NEWS - 2011
Interface Biologics Announces $1 Million Investment By Ontario’s Investment Accelerator Fund – Life Sciences
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, announces a $1 million investment by the Investment Accelerator Fund-Life Sciences (IAF-LS).
Interface Biologics announces Licensing Agreement with Navilyst Medical
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce a definitive license and supply agreement with Navilyst Medical, a leading manufacturer of image-guided medical technologies. Under this agreement, Navilyst Medical has exclusive access to incorporate IBI's Endexo™ technology in its vascular access products.
Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (NYSE: FMS), the worlds' largest integrated provider of dialysis products and services, has executed their option of an exclusive licensing agreement following a successful evaluation period.
Interface Biologics Announces New VP Finance
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the addition of Mr. Kevin Palmer to the IBI management team as Vice President of Finance.
Interface Biologics Appoints Art Rosenthal to Chairman of its Board of Directors
Toronto, Canada, February 14th, 2011 – For Immediate Release
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Arthur L. Rosenthal to Chairman of its Board of Directors.
Interface Biologics Financing Deal Gives A New Face to Biomedical Polymer Technology
At work developing transformative biomedical-polymer products, Interface Biologics, a private company, has recently completed a $7M series B financing led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners.
Interface Biologics Announces $7M Financing
Toronto, Canada, January 10th, 2011 – For Immediate Release
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the completion of a $7M series B financing, led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners.
Interface Biologics - BASF Future Business Collaborate
Toronto, Canada, January 4, 2011 - For Immediate Release
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the signing of a joint development agreement with BASF Future Business GmbH to collaborate in the development of new polymeric formulations with antimicrobial and anti-thrombogenic properties. By joining IBI's anti-thrombogenic technology with BASF's proprietary anti-microbial technology platform, a combined effect can be achieved that will lead to new materials that can substantially improve the safety and performance of medical devices.